A CE Dojo clinical note
A claim keeps circulating in dental circles: clindamycin has no role in dentistry anymore, it’s been pulled from the formulary, there’s no reason to use it. It gets repeated with confidence, usually pointing at the 2021 AHA and ADA update. The confidence is the problem, because the claim folds two different clinical questions into one and gets both wrong.
Here’s the distinction that clears it up.
Prophylaxis and treatment are not the same question
In 2021, the AHA and ADA removed clindamycin from the antibiotic prophylaxis regimen. That’s the pre-procedure dose given to prevent infective endocarditis in at-risk patients. The reasoning was sound. For a single preventive dose in an otherwise healthy mouth, the risk of C. difficile and severe reactions outweighs the benefit. The prophylaxis alternatives became cephalexin, azithromycin or clarithromycin, and doxycycline.
That change was about prevention. Treating an active infection is a separate matter, and the guidance is different.
The ADA’s 2019 guideline on antibiotics for pulpal and periapical conditions still lists clindamycin, 300 mg 4 times a day, as an option for the documented penicillin-allergic patient, alongside azithromycin. It carries an explicit caution that clindamycin raises C. diff risk even after a single dose. It was cautioned, not deleted.
So when someone says clindamycin has “no role,” the useful question back is: which role? Prophylaxis in a healthy mouth and treatment of a spreading infection in a penicillin-allergic patient are not the same decision.
Start with whether an antibiotic is even needed
Before the drug choice, there’s a more basic question that decides most cases. Does this patient actually need an antibiotic?
A lot of what presents as “infection” is pulpitis. Pulpitis is treated by removing the source: pulpotomy, pulpectomy, root canal, or extraction. The ADA is explicit that for localized pulpal and periapical conditions in a healthy adult, definitive dental treatment comes first, and antibiotics are held for systemic involvement, meaning fever, malaise, or spreading swelling.
An antibiotic handed out in place of drainage or definitive treatment does nothing for the tooth. It looks like care and buys a little time. The patient still has the disease when the course runs out.
Verify the allergy before you reach for a second-line drug
Most reported penicillin allergies aren’t true allergies, and penicillin or amoxicillin remains first-line for odontogenic infection. This is where PEN-FAST helps. It’s a validated clinical decision rule built on three items: whether the reaction was within the last 5 years, whether it was anaphylaxis or a severe skin reaction, and whether it required treatment. A low score flags a low-risk patient who often doesn’t need a second-line agent at all.
Working the allergy history changes the drug you reach for, and frequently removes the question entirely.
The alternatives are genuinely limited
Part of why the “just avoid clindamycin” reflex causes trouble is that the bench past penicillin is thin. Azithromycin has weak anaerobic coverage and QT prolongation. First-generation cephalosporins are unimpressive against the anaerobes that matter here. Fluoroquinolones carry connective-tissue risk, including tendon rupture and aortic events, and aren’t a casual dental substitute. That short list is exactly why clindamycin held its place for the truly penicillin-allergic patient.
A dosing habit worth dropping
One more thing worth naming, because it costs real outcomes: Augmentin 875/125 twice daily for dentoalveolar infection.
The shortfall is pharmacokinetic, not a coverage gap in the drug. Amoxicillin with clavulanate is a time-dependent beta-lactam, so what matters is the time the free drug stays above the MIC. Twice-daily dosing leaves longer troughs than every-8-hour dosing. On top of that, 875 twice daily delivers 250 mg of clavulanate a day, while 500 three times daily delivers 375. Clavulanate’s half-life is only about an hour, so in those longer gaps the beta-lactamase-producing anaerobes that populate these polymicrobial infections go back to breaking down the amoxicillin. The molecule has the coverage. The twice-daily schedule doesn’t sustain it.
Resistance and documentation
Resistance is the slow cost people skip. Patients who cycle through course after course while the actual infection goes untreated select for tougher organisms every time. Document the diagnosis, the allergy history, the indication, and the plan. It’s good medicine, and it’s your protection if a case ever turns litigious.
The bottom line
C. diff is real and clindamycin is a known offender. Nobody serious waves that off. But colitis is a risk across nearly the whole antibiotic class, and how we prescribe drives that risk more than any single molecule does.
Given a correct diagnosis, a documented penicillin allergy, and a real indication like a spreading swelling, abscess, or cellulitis, clindamycin remains a defensible choice. The patient has the disease, not the guideline.
That’s the kind of thinking we teach at CE Dojo: sourced, independent CE from clinicians who actually do the work.
Sources
- ADA 2019 guideline on antibiotics for pulpal and periapical pain and swelling (JADA, Nov 2019): https://jada.ada.org/article/S0002-8177(19)30617-8/fulltext
- ADA topic page, antibiotics for dental pain and swelling: https://www.ada.org/resources/research/science/evidence-based-dental-research/antibiotics-for-dental-pain-and-swelling
- ADA antibiotic prophylaxis (2021 update summary): https://www.ada.org/resources/ada-library/oral-health-topics/antibiotic-prophylaxis
- PEN-FAST validation (Int J Infect Dis): https://www.ijidonline.com/article/S1201-9712(20)30975-9/fulltext
- Amoxicillin-clavulanate PK/PD and dosing frequency (BMC Pharmacol Toxicol): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4129431/